OAM
VIR icon

Oxford Asset Management’s Vir Biotechnology VIR Stock Holding History

Oxford Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,626
Closed -$127K – 774
2025
Q1 		$127K Buy
+19,626
New +$174K 0.06% 408

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oxford Asset Management's VIR Position: Q2 2025 in Review

Oxford Asset Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 19,626 shares — an estimated $127K sold.

Oxford Asset Management first reported a position in VIR in Q1 2025 and held it in 1 quarter. The position peaked at $127K in Q1 2025. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Oxford Asset Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Oxford Asset Management sold 19,626 Vir Biotechnology shares in Q2 2025, an estimated $127K.
  • Oxford Asset Management first reported a position in Vir Biotechnology in Q1 2025 and held it in 1 quarter.
  • Oxford Asset Management's Vir Biotechnology position peaked at $127K in Q1 2025.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Oxford Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.